当前位置: 首页 > 期刊 > 《中国现代医生》 > 2012年第12期
编号:12220381
丙氨瑞林对子宫内膜癌裸鼠移植瘤的生长及FHIT表达的影响(2)
http://www.100md.com 2012年4月25日 《中国现代医生》 2012年第12期
     综上所述,GnRH及其类似物在一定程度上可以抑制子宫内膜癌的生长,其可能作为子宫内膜癌内分泌治疗的一种有效药物来应用,因此展示在肿瘤患者面前的将是一个广阔的前景。

    [参考文献]

    [1]Gallagher CJ,Oliver RT,Oram DH,et al. A new treatment for endometrial cancer with gonadotrophin releasing-hormone[J]. Br J Obstet Gynaecol,1991,98(10):1037-1041.

    [2]张玉泉,曹斌融,周先荣,等. 丙氨瑞林治疗子宫内膜癌后性激素及有丝分裂指数的变化[J]. 新药与临床,1996,15(4):1942-1961.

    [3]Grundker C,Gunthert AR,Westphalen S,et al. Biology of the gonadotrophin-releasing hormone system in gynecological cancers[J]. Eur J Endocrinol,2002,146(1):1-14.

    [4]Wang CB,Wang CJ,Huang HJ,et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma[J]. Cancer,2002,94(8):2192-2198.

    [5]Segawa T,Sasagawa T,Saijoh K,et al. Clinicopathological significance of fragile histidine triad transcription protein expression in endometrial carcinomas[J]. Clin Cancer Res,2000,6(6):2341-2348.

    [6]Ishii H,Dumon KR,Vecchione A,et al. Effect of adenoviral transduction of the fragile histidine trad gene into esophageal cancer cells[J]. Cancer Res,2001,61(4):1578-1584.

    [7]Su TH,Wang JC,Tseng HH,et al. Analysis of FHIT transcripts in cervical and endometrial cancers[J]. Int J Cancer,1998,76(2):216-222.

    [8]Ozaki K,Enomoto T,Yoshino K,et al. FHIT alterations in endometrial carcinoma and hyperplasia[J]. Int J Cancer,2000,85(3):306-312.

    (收稿日期:2012-02-02), http://www.100md.com(杜丽英 张三元)
上一页1 2